MediGene

MediGene AG

Type	Aktiengesellschaft
Traded as	FWB: MDG
Industry	Biotechnology
Predecessor	Munich Gene Center
Founded	1994 (1994)
Headquarters	Martinsried, Germany
Key people	Frank Mathias (CEO), Ernst-Ludwig Winnacker (Chairman of the supervisory board)
Products	Pharmaceuticals for treatment of cancer and autoimmune diseases
Revenue	€37.9 million (2009)[1]
Operating income	(€19.6 million) (2009)[1]
Profit	(€22.0 million) (2009)[1]
Employees	110 (end 2009)[1]
Website	www.medigene.de

MediGene AG is a German biotechnology company. It is involved in the development of anti pancreatic cancer drugs.^[2] The company has two marketed products: Eligard (leuprorelin) for prostate cancer and Veregen (sinecatechins) for genital warts. It has three other products in clinical development for the treatment of hormone-resistant breast cancer, pancreatic cancer and rheumatoid arthritis.

References

1. ^ ^{a b c d} "Annual Report 2009". MediGene. http://www.medigene.de/mediadb/9739/9740/AnnualReport2009.pdf. Retrieved 22 August 2010. 
2. ^ "MediGene drug extends pancreatic cancer survival". Reuters. 2008-09-18. http://www.reuters.com/article/marketsNews/idUSLG43985820080916?sp=true. 

External links

• Official website